Key points are not available for this paper at this time.
Key Points Rituximab prevents steroid-requiring chronic graft-vs-host disease when given after peripheral blood stem cell transplantation. Overall survival is improved with rituximab after allogeneic peripheral blood stem cell transplantation when compared with a control cohort.
Cutler et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: